REGEnLIFE : une révolution dans le traitement des maladies neurodégénératives
Founded 8 years ago, REGEnLIFE is a company specializing in the development of non-invasive therapeutic treatments for neurological diseases, particularly neurodegenerative disorders. An innovative medtech, REGEnLIFE’s mission is to improve the health and daily lives of patients suffering from disabling neurological conditions, thanks to a unique technology called tri-phonic stimulation.
In an exclusive interview with Patrice Cristofini, CEO of REGEnLIFE, we take a look at this disruptive, patented, non-invasive, drug-free technology, which aims to revolutionize the treatment of neurological diseases.
A unique approach: tri-photonic stimulation
The innovation developed by REGEnLIFE is based on a unique medical device combining a helmet with head-mounted modules and an abdominal belt. “This device simultaneously stimulates the brain and the intestine, by sending specific tri-phonic stimulations,” explains Patrice Cristofini.
“We’re the only company in the world to treat the brain and the abdominal girdle at the same time. The second singularity lies in this tri-phonic stimulation by light. Thanks to the power of the light, photons penetrate cells, in particular neurons, and help regenerate them by acting on the mitochondria.” This technology has been patented internationally.
Major therapeutic applications
REGEnLIFE is working on two major subjects in the clinical phase and two in the pre-clinical phase.
Alzheimer’s: a breakthrough in the clinical phase
Today, there is no treatment that can permanently halt the progression of Alzheimer’s disease. REGEnLIFE intends to change all that. Following an initial study in 2022, a new multi-center human study is now underway. It involves several university hospitals and aims to demonstrate the treatment’s efficacy on 108 patients, in a double-blind clinical trial. The aim is to prove that six months after a treatment session, patients show measurable and stable improvement. Results are expected by the end of 2025.
Acute concussion: convincing clinical results
Acute concussions, common among top-level athletes, can lead to long-term sequelae. REGEnLIFE conducted a study on 50 people suffering from acute concussion, with approved results. A real improvement in symptoms was observed. REGEnLIFE is currently working on European marking of the device and on marketing authorization for acute concussions.
Promising pre-clinical prospects
In the pre-clinical phase, REGEnLIFE has also achieved remarkable results in multiple sclerosis, with animal model studies showing a significant reduction in inflammation. This breakthrough opens the way to non-invasive therapeutic solutions for this autoimmune disease. The company also intends to explore the treatment of resistant depression, a major challenge in psychiatry. Human clinical trials could be launched with the funds raised.
Strategic fundraising
To make these advances a reality, REGEnLIFE has launched a €8.5 million fund-raising campaign. This sum will be used to finalize the Alzheimer’s clinical study, accelerate the CE mark process, develop new clinical studies and prepare for industrialization and marketing of the device by 2026. “We are at a turning point,” concludes Patrice Cristofini.
